Klaus Lindpaintner, MD, MPH, FACP previously held senior positions at Pfizer as Global Head, Human Genetics and Computational Biomedicine, at Hoffmann-La Roche, spearheading the company’s efforts in personalized health care; as CSO at Thermo-Fisher-Scientific; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professor-ships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities, and non-governmental organizations.
Clinical & Research Tools Showcase:
InterVenn harnesses the elusive power of glycoproteomics for the discovery and development of high accuracy novel diagnostic, predictive, and prognostic markers as well as for discovery and validation of uniquely powerful new drug targets.
Harnessing The Power Of Glycoproteomics For Personalized Health Care
While genetics/genomics has facilitated impressive progress in the life sciences, its constraints based on the finite complexity and dynamic range of genomic data compared to the proteomeare becoming increasingly a limitation with regard to actionable clinical applicability. InterVenn has developed an AI-ML-empowered LC/MS platform that harnesses the vastly larger complexity and dynamic range of the proteome, in particular, the glycoproteome, and thus information content, rendering analytical performance of unprecedented accuracy.
The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.